Phase I clinical trial - Sein Néoadjuvant
EMBER-2 (J2J-MC-JZLB)
Sein Néoadjuvant
Ouvert depuis le: 07.27.2024
Site: Saint-Cloud
Public cible
Adulte
EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Description de l'essai
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.
Liens utiles
FRANCOIS-CLEMENT BIDARD
Investigateur principal